质子泵抑制剂对接受免疫检查点抑制剂治疗的肺鳞状细胞癌患者预后的影响

杨俊娥 ,  杜英丽 ,  石庆芳

中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (10) : 953 -957.

PDF (351KB)
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (10) : 953 -957. DOI: 10.12007/j.issn.0258‐4646.2026.10.016
短篇论著

质子泵抑制剂对接受免疫检查点抑制剂治疗的肺鳞状细胞癌患者预后的影响

作者信息 +

Prognosis of patients with lung squamous cell carcinoma receiving concomitant proton pump inhibitor and immune checkpoint inhibitor therapy

Author information +
文章历史 +
PDF (358K)

摘要

通过回顾性队列研究,探讨质子泵抑制剂 (PPI) 对接受免疫检查点抑制剂 (ICI) 治疗的122例肺鳞状细胞癌患者预后的影响。单因素分析结果显示,美国东部肿瘤协作组 (ECOG) 评分0~1分患者的中位无进展生存期 (PFS) 和中位总生存期 (OS) 明显大于ECOG评分2分的患者,无肝转移患者的中位PFS和中位OS明显大于有肝转移的患者,无脑转移患者的中位OS明显大于有脑转移的患者,未合并使用PPI患者的中位OS明显大于合并使用PPI的患者 (均P<0.05)。多因素分析结果显示,EOCG评分是肺鳞状细胞癌患者中位PFS较短的独立危险因素,肝转移和合并使用PPI为患者中位OS较短的独立危险因素 (均P<0.05)。结果提示,ICI治疗合并使用PPI可能导致肺鳞状细胞癌患者预后不良,应充分考虑合并用药的可能获益和风险,谨慎评估PPI治疗肺鳞状细胞癌的适应证和必要性。

关键词

肺鳞状细胞癌 / 免疫检查点抑制剂 / 质子泵抑制剂 / 预后

Key words

引用本文

引用格式 ▾
杨俊娥,杜英丽,石庆芳. 质子泵抑制剂对接受免疫检查点抑制剂治疗的肺鳞状细胞癌患者预后的影响[J]. 中国医科大学学报, 2026, 55(10): 953-957 DOI:10.12007/j.issn.0258‐4646.2026.10.016

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Boedtkjer E,Pedersen S F. The acidic tumor microenvironment as a driver of cancer [J]. Annu Rev Physiol,2020,82:103-126. DOI:10.1146/annurev-physiol-021119-034627.

[2]

Bellone M,Calcinotto A,Filipazzi P,et al. The acidity of the tumor microenvironment is a mechanism of immune escape that can be over come by proton pump inhibitors [J]. Oncoimmunology,2013,2 (1):e22058. DOI:10.4161/onci.22058.

[3]

Kawachi H,Yamada T,Tamiya M,et al. Concomitant proton pump inhibitor use with pembrolizumab monotherapy vs immune check point inhibitor plus chemotherapy in patients with non-small cell lung cancer [J]. JAMA Netw Open,2023,6 (7):e2322915. DOI:10.1001/ jamanetworkopen.2023.22915.

[4]

Wang B Y,Zhang J,Wang J L,et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer [J]. J Exp Clin Cancer Res,2015,34 (1):85. DOI:10.1186/s13046-015-0194-x.

[5]

Elli C,Novella A,Pasina L,et al. Proton pump inhibitors and 1-year risk of adverse outcomes after discharge from internal medicine wards:an observational study in the REPOSI cohort [J]. Intern Emerg Med,2025,20 (4):1119-1126. DOI:10.1007/s11739-025-03937-z.

[6]

Roudgar S,Joukar F,Mojtahedi K,et al. Prevalence and factors as sociated with proton pump inhibitors (PPIs) use:a cross-sectional study of PERSIAN guilan cohort study [J]. Heal Sci Rep,2025,8 (2):e70494. DOI:10.1002/hsr2.70494.

[7]

Sun G Y,Edwards D M,Miller S R,et al. Association of proton pump inhibitor use and severe pneumonitis in stage Ⅲ non-small- cell lung cancer treated with primary chemoradiation and adjuvant durvalumab [J]. Int J Radiat Oncol,2023,117 (2):e61. DOI:10.1016/j.ijrobp.2023.06.780.

[8]

Baek Y H,Kang E J,Hong S,et al. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibi- tors and immune checkpoint inhibitors [J]. Int J Cancer,2022,150 (8):1291-1300. DOI:10.1002/ijc.33892.

[9]

Jackson M A,Goodrich J K,Maxan M E,et al. Proton pump inhibitors alter the composition of the gut microbiota [J]. Gut,2016,65 (5):749-756. DOI:10.1136/gutjnl-2015-310861

[10]

Strzępa A,Marcińska K,Kiecka A,et al. Proton pump inhibitor alters Th17/Treg balance and induces gut dysbiosis suppressing con tact hypersensitivity reaction in mice [J]. Front Immunol,2024,15:1390025. DOI:10.3389/fimmu.2024.1390025.

基金资助

河北省医学科学研究课题计划(20242200)

AI Summary AI Mindmap
PDF (351KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉